Pancreatic Neuroendocrine Tumor (pNET)
Oncology·MeSH: Adenoma, Islet Cell
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| zanzalintinib | EXELIXIS, INC. (EXEL) |
Frequently asked questions
How many drugs are in development for Pancreatic Neuroendocrine Tumor (pNET)?
BioSniper tracks 1 drug in development for Pancreatic Neuroendocrine Tumor (pNET) across 1 company.
How many clinical trials target Pancreatic Neuroendocrine Tumor (pNET)?
There are 1 clinical trial targeting Pancreatic Neuroendocrine Tumor (pNET) tracked by BioSniper.
What is the prevalence of Pancreatic Neuroendocrine Tumor (pNET)?
The estimated prevalence of Pancreatic Neuroendocrine Tumor (pNET) is approximately 30.0 per 100,000 population.
Deep-dive into Pancreatic Neuroendocrine Tumor (pNET)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis